Thursday 7 May, 2026
Introduction: Tuberculous meningitis (TBM) manifests as the most devastating form of paediatric tuberculosis, causing high mortality rates and neurological sequelae…
Read moreAbstracts
EXPOSURE-RESPONSE RELATIONSHIP OF ONCE-MONTHLY SUBCUTANEOUS OLANZAPINE (TV-44749) FOR THE CLINICAL GLOBAL IMPRESSION-SEVERITY SCALE IN PATIENTS WITH SCHIZOPHRENIA
Thursday 7 May, 2026
Introduction/Objectives: Olanzapine is a second-generation antipsychotic drug available in oral, intramuscular (IM) immediate release, and IM long-acting injectable (LAI) formulations….
Read morePopulation pharmacokinetics of an oral combination of decitabine and tetrahydrouridine in healthy volunteers
Thursday 7 May, 2026
Objectives: Sickle cell disease (SCD) is driven by polymerization of mutated hemoglobin in red blood cells [1]. Fetal hemoglobin (HbF)…
Read morePHARMACOKINETICS OF HPMZ TREATMENT IN CYNOMOLGUS MACAQUES: RECOMMENDATIONS FOR A PROSPECTIVE EFFICACY STUDY WITH ANTITUBERCULAR DRUGS.
Thursday 7 May, 2026
Introduction: Tuberculosis (TB) remains a leading cause of death from a single infectious agent worldwide[1]. Efforts in shortening anti-TB therapy…
Read moreModelling SARS-CoV-2-specific antibody responses to personalize vaccination strategies as a tool for pandemic preparedness
Thursday 7 May, 2026
Objectives During the pandemic, COVID-19 vaccines were administered to prevent severe disease [1]. Variable immune responses were observed in controls…
Read moreON THE USE OF TECOVIRIMAT FOR MPXV INFECTIONS: WHY DO WE NOT SEE SHORTENED TIMES TO VIRAL CLEARANCE IN TREATED PATIENTS?
Thursday 7 May, 2026
Introduction: Before 2022, mpox (formerly known as `monkeypox’) was primarily circulating in endemic areas (West and Central Africa) with sporadic…
Read moreDevelopment of an In-Silico Platform to Explore HIV Incidence Across Different Regions and Its Application to PrEP Clinical Trials for Treatment Design and Optimization
Thursday 7 May, 2026
Introduction. Human immunodeficiency virus (HIV) remains a major global public health challenge, affecting millions worldwide, with the highest prevalence in…
Read moreTranslational pharmacology and optimisation of a first-time-in-children protocol for the evaluation of the safety, tolerability, pharmacokinetics and preliminary efficacy of BGA002 in refractory MYCN-altered tumours.
Thursday 7 May, 2026
Introduction MYCN is a key oncogenic driver in several paediatric malignancies, including neuroblastoma, where its amplification is associated with rapid…
Read moreMODEL-INFORMED DRUG DEVELOPMENT TO SUPPORT DOSE SELECTION OF PASRITAMIG, A KLK2×CD3 BISPECIFIC ANTIBODY, IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Thursday 7 May, 2026
Objective To support the development of pasritamig, a KLK2×CD3 bispecific T‑cell engager, through model‑informed drug development (MIDD) methodologies, integrating population…
Read moreStructural Identifiability Analysis of Ghost Payload Dynamics in Antibody-Drug Conjugate Pharmacokinetic Models: A Minimal DAR2 Framework
Thursday 7 May, 2026
Introduction/Objectives Antibody-drug conjugates (ADCs) present unique pharmacokinetic challenges arising from the interplay between antibody disposition, payload deconjugation, and the fate…
Read more